Benzinga | Aug 6, 2020 09:14AM EDT

Autolus Therapeutics Earlier Reported Q2 EPS $(0.62) Beats $(0.71) Estimate, Sales $293.00K Miss $440.00K Estimate

Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.71) by 12.68 percent. This is a 4.62 percent increase over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $293.00 thousand which missed the analyst consensus estimate of $440.00 thousand by 33.41 percent. This is a 13.31 percent decrease over sales of $338.00 thousand the same period last year.